All In Biotech

Drug Trial Radar · NCT03568383

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 5,832 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

5,832

Actual

Start

Jun 3, 2019

Primary completion

Nov 16, 2026

Study completion Nov 16, 2026

Sponsor

Sponsor type
NIH
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Otsuka Pharmaceutical Development & Commercialization, Inc.
First posted
Jun 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases). High-risk HHCs are those with HIV or non-HIV immunosuppression, latent TB infection, and young children below the age of 5 years.

Conditions

  • Tuberculosis, MDR

Interventions

  • Delamanid (DLM)Drug

    Adults and children ≥30 kg: delamanid 200 mg orally once daily. Children ≥2.5 kg to \<30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits.

  • Isoniazid (INH)Drug

    Adults and children ≥24 kg: INH 300 mg orally once daily. Children ≥2.5 kg to \<24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted.

  • Pyridoxine (vitamin B6)Dietary supplement

    All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of participants with confirmed or probable active TB at any time between Day 0 and the week 96 study visitTime frame: Measured through Week 96
  2. Percent of participants who permanently discontinue randomized study drug (DLM or INH) due to a treatment-related adverse eventTime frame: Measured through Week 96

Locations

31 sites in 13 countries. Site status is shown where the registry gives one.

  • Gaborone CRS

    Gaborone, South-East District, Botswana

  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

    Rio de Janeiro, Rio de Janeiro, Brazil

  • GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS

    Port-au-Prince, Haiti

  • Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS

    Port-au-Prince, Haiti

  • Byramjee Jeejeebhoy Government Medical College (BJGMC) CRS

    Pune, Maharashtra, India

  • YRG CARE CRS [Site ID: 32075]

    Chennai, Tamil Nadu, India

  • Moi University Clinical Research Center (MUCRC) CRS

    Eldoret, Rift Valley, Kenya

  • Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS

    Kericho, Rift Valley, Kenya

  • Barranco CRS

    Lima, Peru

  • San Miguel CRS

    Lima, Peru

  • Socios En Salud Sucursal Perú CRS

    Lima, Lima Province, Peru

  • TB HIV Innovations and Clinical Research Foundation Corp.

    Silang, Cavite, Philippines

  • CAPRISA eThekwini CRS

    Durban, South Africa

  • Soweto ACTG CRS

    Johannesburg, Gauteng, South Africa

  • Wits Helen Joseph Hospital CRS (Wits HJH CRS)

    Johannesburg, Gauteng, South Africa

  • Durban International Clinical Research Site CRS

    Durban, KwaZulu-Natal, South Africa

  • PHRU Matlosana CRS

    Klerksdorp, North West, South Africa

  • Rustenburg CRS

    Rustenburg, North West, South Africa

  • Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS

    Cape Town, Western Cape, South Africa

  • Task Applied Science (TASK) CRS

    Cape Town, Western Cape, South Africa

  • University of Cape Town Lung (UCTL) CRS

    Cape Town, Western Cape, South Africa

  • South African Tuberculosis Vaccine Initiative (SATVI) CRS

    Cape Town, Western Cape, South Africa

  • Kilimanjaro Christian Medical Centre (KCMC)

    Moshi, Tanzania

  • Chiangrai Prachanukroh Hospital NICHD CRS

    Chiang Mai, Thailand

  • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS

    Pathum Wan, Bangkok, Thailand

  • Siriraj Hospital ,Mahidol University NICHD CRS

    Bangkok, Bangkoknoi, Thailand

  • Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site

    Kampala, Uganda

  • MU-JHU Research Collaboration (MUJHU CARE LTD) CRS

    Kampala, Uganda

  • National Lung Hospital CRS (Site ID: 32483)

    Vĩnh Phúc, Hanoi, Vietnam

  • Vietnam-University of Sydney CRS Site# 32495

    Ho Chi Minh City, Vietnam, Vietnam

  • Milton Park CRS

    Milton Park, Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.